Walmart, the world's largest retailer, delivered a solid third quarter and raised its full-year sales forecast, signaling that shoppers are still spending even as the broader economy cools. The company now expects net sales growth of 4.9% to 5.2% in constant currency, up from its previous guidance.
The results beat Wall Street's two headline checks: revenue came in at $188.84 billion versus the $187.27 billion analysts had penciled in, and adjusted earnings per share of $0.65 edged past the $0.64 consensus. In the U.S., comparable sales excluding fuel rose 2.9%, roughly in line with expectations, giving management room to lift its full-year adjusted EPS range to $2.84-$2.89 from $2.80-$2.87.
What's driving the numbers
Under the surface, there were a few moving parts. Walmart International looked weaker on paper, but that was largely due to timing. Flipkart's Big Billion Days sales event shifted into the fourth quarter, shaving about 500 basis points off the segment's net sales growth in Q3. That demand is expected to land in Q4 instead. Currency swings also added $1.2 billion to international sales.
The bigger drag came from Health and Wellness. Walmart said drug-price deflation tied to “maximum fair price” regulation created a roughly 70-basis-point headwind to overall comparable sales. That's a reminder that even the biggest retailers aren't immune to policy-driven pricing pressure.
The GLP-1 factor fades
One of the more notable signals in the report was about the future. Walmart said the comparable-sales tailwind from GLP-1 weight-loss drugs will cool over time. It expects that boost to be about 60 basis points in fiscal 2027, down from roughly 100 basis points in fiscal 2025 and 2026.
For investors, that's a subtle but important shift. GLP-1 medications have been a quiet helper for same-store growth, as customers buying these drugs also tend to buy more groceries and other items. As that benefit fades, more of Walmart's growth will need to come from the core retail engine: customer traffic, average basket size, and product mix.
That changes what investors lean on when they look past the next quarter. With less help baked in, longer-dated expectations can become more sensitive to any wobble in underlying comparable sales. That's why consensus targets, like the IBES view of $2.88 in earnings per share on $752.65 billion of revenue for fiscal 2027, could become harder to underwrite if the core business stumbles.
What it means for investors
For everyday investors, the takeaway is twofold. First, Walmart's raised outlook is a positive sign for the consumer. When the world's largest retailer feels confident enough to lift its forecast, it suggests that spending, at least at the mass-market level, remains resilient.
Second, the GLP-1 commentary is a reminder that even reliable growth drivers don't last forever. Companies that have benefited from a tailwind—whether it's a drug trend, a pandemic boom, or a currency shift—eventually face a tougher comparison. Investors should watch whether Walmart can sustain its momentum without that crutch.
Walmart's results also come at a time when other retailers are sending mixed signals. JD Sports recently cut its profit forecast as sales slipped, and a2 Milk trimmed its outlook on a slow China recovery. Walmart's strength stands out against that backdrop, but it also highlights how uneven the retail landscape is.
Looking ahead, investors will be watching how Walmart manages the shift in its sales mix, whether it can keep traffic growing, and how it navigates ongoing drug-price pressures. The company's ability to raise guidance suggests it's confident in the near term, but the fading GLP-1 boost is a reminder that the longer-term picture requires more from the core business.
For a broader view of how Walmart's strategy is playing out, this look at its recent momentum offers useful context.


